drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Autologous patient T cells genetically engineered to express a chimeric antigen receptor that co-recognizes CD38 and CS1 (SLAMF7) on myeloma cells, triggering T-cell cytotoxicity to treat relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a dual-target chimeric antigen receptor that co-recognizes CD38 and CS1 (SLAMF7) on myeloma cells; antigen binding activates CAR signaling (CD3zeta with costimulation), triggering perforin/granzyme release and cytokine-mediated killing of CD38+ and/or CS1+ malignant plasma cells, reducing antigen-loss escape.
drug_name
CD38/CS1 dual-target CAR T cells
nct_id_drug_ref
NCT06574958